Last reviewed · How we verify

GRADE Study Group — Portfolio Competitive Intelligence Brief

GRADE Study Group pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sulfonylurea (glimepiride) Sulfonylurea (glimepiride) phase 3 Sulfonylurea SUR1/ Kir6.2 Diabetes
DPP-4 inhibitor (sitagliptin) DPP-4 inhibitor (sitagliptin) phase 3 DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4) Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 2 shared drug classes
  2. Sanofi · 2 shared drug classes
  3. Al-Azhar University · 1 shared drug class
  4. Bial - Portela C S.A. · 1 shared drug class
  5. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
  6. Cinnagen · 1 shared drug class
  7. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GRADE Study Group:

Cite this brief

Drug Landscape (2026). GRADE Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grade-study-group. Accessed 2026-05-13.

Related